Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effect of Gastric Electrical Stimulation on Serum Insulin Levels

11 augusti 2026 uppdaterad av: Thomas V. Nowak, Indiana University

Defining the Effect of Gastric Electrical Stimulation on Serum Insulin Levels in Human Subjects

The goal of this observational study is to determine how much effect turning the subject's Gastric Electrical Stimulator off for up to four hours will have on levels of insulin, C-peptide, GLP-1 and Glucose levels in patients with gastroparesis who have had a GES for at least three months, who are not taking diabetic prescribed exogenous insulin. EKG recordings will be made and analyzed for Heart Rate Variability and Power Spectral Analysis.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

Up to thirty-two adult patients with gastroparesis who have undergone implantation of a gastric stimulation device at least three months prior are candidates for study. Diabetic patients who are taking exogenous insulin are excluded from study The study consists of two groups, an EXPERIMENTAL group that undergoes turning off the GES and a CONTROL group that does not undergo the turning off of the GES. The subjects are randomized to either the control or experimental group. The study Coordinator will create a block randomization schedule in Excel (Block Randomization in Clinical Trials: Video Tutorial in Microsoft Excel)(10). The study Coordinator will use the Excel randomization schedule to assign the treatment and will administer the stimulus accordingly. No one will be blinded to any of the arms of the study.

After an overnight fast, the patients are placed in the supine position on a hospital bed, and an intravenous line is inserted and capped. The study consists of three separate and consecutive periods: 1. Baseline, a 20-minute period during which GES is left ON at each patient's pre-study settings; 2. Experimental, a 4-hour period during which the GES device is turned OFF; 3. Recovery, a 20-minute period during which GES is turned back ON to the patient's pre-study settings. A 5-ml sample of blood will be removed from each patient after placement of the flexible IV catheter secured with tape, the Baseline, and Recovery study periods. During the Experimental period a blood sample is withdrawn after 30 minutes and then again at the 1-hour, 2-hour, 3-hour and 4-hour intervals through a flexible IV catheter secured with tape , with the possibility of up to 8 blood draws over the duration of the study.

Plasma samples are analyzed for glucose, C-peptide, GLP-1 and insulin levels. The analysis of variance is used to determine whether there is any significant effect of time on the resultant values. In a previous study we examined the variance of patient demographics (age, gender, and BMI). As patients with implanted electrical stimulators typically have different stimulator settings to control their symptoms, this arm of the study examines whether stimulation parameters such as pulse duration, amplitude or frequency have any effect on individual response to gastric electrical stimulation. A correlation coefficient analysis is used to determine if any variable shows a significant effect.

During the study EKG electrodes are placed over the extremities and precordium and recordings continued during the respective Baseline, Experimental, and Recovery periods. EKG signals are digitized and downloaded to a computer for time domain power spectral analysis of heart rate variability using commercially available software. This analysis will determine the influence of sympathetic and parasympathetic mechanisms during the respective time periods.

Studietyp

Interventionell

Inskrivning (Beräknad)

32

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Thomas V Nowak, MD
  • Telefonnummer: 3179484272
  • E-post: tvnowak@iu.edu

Studera Kontakt Backup

  • Namn: Maureen V Schilling, BA
  • Telefonnummer: 3172782064
  • E-post: maschi@iu.edu

Studieorter

    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Rekrytering
        • Indiana University Hospital
        • Kontakt:
        • Kontakt:
          • Maureen Schilling, BA
          • Telefonnummer: 317-278-2064
          • E-post: maschi@iu.edu

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • • At least 18 years of age.

    • Documented diagnosis of gastroparesis
    • Not taking diabetic prescribed exogenous insulin.
    • Patient has a GES device that has been implanted for at least 3 months.
    • Willing to give up to 8 blood samples.
    • Willing to lie in a bed for up to 5.5 hours.

Exclusion Criteria:

  • • Pregnancy

    • History of allergic reaction to EKG lead placement adhesives.
    • Unable to give informed consent.
    • Unwilling to give up to 8 5 ml blood samples.
    • Unwilling to lie in a bed for up to 5.5 hours.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Hälsovårdsforskning
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: The OFF Group
This group of subjects will have their GES interrogated and observed as well as having the device turned off for the duration of the experiment. The device will then be re-interrogated and turned back on at the end of the experiment.
Device will either be turned off for the duration of the experiment, or the device will be left on for the duration of the experiment
Andra namn:
  • GES
Sham Comparator: SHAM Group
This group of subjects will have their GES interrogated and observed yet will not have the device turned off for the duration of the experiment. The device will then be re-interrogated at the end of the experiment. This is to retain the illusion of the device being turned back on.
Device will either be turned off for the duration of the experiment, or the device will be left on for the duration of the experiment
Andra namn:
  • GES

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Definition of Effect
Tidsram: Day 1
To define the effect of prolonged four-hour withdrawal of gastric electrical stimulation on serum insulin and C-peptide levels in human subjects. Insulin and C-peptide are co-primary end points.
Day 1

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Comparing Hormone Levels
Tidsram: Day 1
To compare the changes in serum insulin and C-peptide levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation.
Day 1
Definition of 4-Hour Withdrawl of GES Device
Tidsram: Day 1
To define the effect of prolonged four-hour withdrawal of gastric electrical stimulation on serum GLP-1 and glucose levels in human subjects. GLP-1 and glucose are co-secondary end points.
Day 1
Changes in Glucose and GLP-1 Levels
Tidsram: Day 1
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation.
Day 1

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Tertiary Objective
Tidsram: Day 1
To determine whether changes noted in serum levels of insulin, C-peptide, GLP-1 and glucose are associated with alterations in heart rate variability and sympathetic and parasympathetic autonomic activation.
Day 1

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Thomas V Nowak, MD, IU School of Medicine/IU Health

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 juli 2026

Primärt slutförande (Beräknad)

31 juli 2028

Avslutad studie (Beräknad)

31 juli 2028

Studieregistreringsdatum

Först inskickad

3 juni 2026

Först inskickad som uppfyllde QC-kriterierna

3 juni 2026

Första postat (Faktisk)

9 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 augusti 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 30020 (DAIDS-ES Registry Number)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera